Pertuzumab

證據等級: L5

預測適應症: 10 個

Pertuzumab: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer

One-Sentence Summary

Pertuzumab is a HER2-targeted monoclonal antibody used in combination regimens for HER2-positive breast cancer. The TxGNN model predicts it may be effective for progesterone-receptor (PR) positive breast cancer, with 10 clinical trials and 20 publications currently supporting this direction — though this largely reflects a hormone-receptor subgroup of the drug’s existing HER2-positive population rather than an independent new indication.

Quick Overview

Item	Content
Original Indication	Not recorded in this evidence pack (no license entries); clinical trial text confirms established use in HER2-positive breast cancer
Predicted New Indication	Progesterone-receptor positive breast cancer
TxGNN Prediction Score	99.93%
Evidence Level	L1
US Market Status	Not Marketed (per this dataset)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (data gap DG002). Based on known information, pertuzumab is a recombinant humanized monoclonal antibody that binds the HER2 extracellular dimerization domain (subdomain II), blocking HER2/HER3 heterodimerization and downstream signaling. It is used in combination with trastuzumab and taxane chemotherapy, and its efficacy in HER2-positive breast cancer has been established through multiple pivotal trials (e.g., NeoSphere, CLEOPATRA-family programs).

PR-positive breast cancer and HER2-positive breast cancer are not mutually exclusive — roughly half of HER2-overexpressing tumors co-express hormone receptors (ER and/or PR). The TxGNN prediction here largely captures this HR+/HER2+ intersection rather than an independent mechanistic extension: pertuzumab’s anti-HER2 activity is only pharmacologically relevant when HER2 is co-expressed. Several trials in the evidence set (e.g., NEOADAPT, PERTAIN, WSG-TP-II) specifically test pertuzumab-based regimens combined with endocrine therapy in HR+/HER2+ patients, supporting the biological plausibility of this indication — but strictly within HER2-positive disease. If a patient is HER2-negative, the mechanistic link does not hold.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00545688	Phase 2	Completed	417	4-arm neoadjuvant study of Herceptin/docetaxel/pertuzumab combinations in HER2+ breast cancer; a key early registration-supporting trial
NCT04629846	Phase 3	Completed	517	QL1209 (pertuzumab biosimilar) vs. reference pertuzumab + docetaxel in early/locally advanced HER2+, ER/PR-negative breast cancer
NCT03726879	Phase 3	Completed	454	IMpassion050: atezolizumab vs. placebo added to neoadjuvant ddAC-PacHP (incl. pertuzumab) in early HER2+ breast cancer
NCT05802225	Phase 3	Active, not recruiting	398	BCD-178 vs. Perjeta as neoadjuvant therapy in HER2+, ER/PR-negative breast cancer
NCT04675827	Phase 2	Terminated	139	DECRESCENDO: de-escalation of adjuvant chemotherapy in HER2+/ER-negative/node-negative early breast cancer after pCR with dual HER2 blockade
NCT02326974	Phase 2	Active, not recruiting	164	T-DM1 + pertuzumab preoperative therapy; examines impact of HER2 heterogeneity on treatment response
NCT00999804	Phase 2	Active, not recruiting	128	TBCRC 023: lapatinib + trastuzumab ± endocrine therapy (12 vs. 24 weeks) in HER2-overexpressing breast cancer
NCT02689921	Phase 2	Unknown	7	NEOADAPT: neoadjuvant aromatase inhibitor + pertuzumab/trastuzumab without chemotherapy in HR+/HER2+ localized breast cancer
NCT06131424	N/A	Completed	1151	Retrospective multicenter study on HER2-low prevalence, treatment patterns and outcomes in metastatic breast cancer
NCT03058939	Phase 2	Withdrawn	0	Weekly neoadjuvant paclitaxel in Nigerian women with breast cancer; withdrawn, no enrollment

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30106636	2018	RCT (Phase 2, PERTAIN)	J Clin Oncol	Trastuzumab + aromatase inhibitor ± pertuzumab as first-line therapy in HER2+/HR+ metastatic/locally advanced breast cancer
28945833	2017	RCT (final analysis)	Ann Oncol	WSG-ADAPT HER2+/HR- trial: 12-week neoadjuvant dual HER2 blockade ± weekly paclitaxel, de-escalation strategy
38906970	2024	RCT (biosimilar equivalence)	Br J Cancer	QL1209 (pertuzumab biosimilar) equivalence trial vs. reference pertuzumab in HER2+, ER/PR-negative breast cancer
37609714	2023	RCT (DECRESCENDO)	Future Oncol	Chemotherapy de-escalation trial design in HR-negative, HER2-positive, node-negative early breast cancer
27179402	2016	Long-term follow-up cohort	Lancet Oncol	NeoSphere 5-year analysis: neoadjuvant pertuzumab + trastuzumab improves pathological complete response
37166817	2023	Comparative cohort	JAMA Oncol	WSG-TP-II: endocrine therapy + trastuzumab/pertuzumab vs. de-escalated chemotherapy in HR+/HER2+ early breast cancer
40282499	2025	Cohort	Cancers	Adjuvant metronomic chemotherapy plus targeted/anti-hormonal therapy proposal for HER2+/ER-PR+ breast cancer
40739524	2025	Real-world cohort	Br J Clin Pharmacol	Real-world treatment patterns in HR-positive metastatic breast cancer in the USA
35640077	2022	Guideline/Review	J Clin Oncol	ASCO guideline update on systemic therapy for advanced HER2-positive breast cancer
27057657	2016	Review	Cancer Treat Rev	Review of HR+/HER2+ breast cancer biology and treatment landscape

US Market Information

Pertuzumab currently has no NDA/license records in this evidence pack (total_licenses = 0, market status “Not Marketed”). No product, dosage form, or approved-indication data is available to tabulate.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (anti-HER2 monoclonal antibody; HER2/HER3 dimerization inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Low as monotherapy; increases to moderate when combined with taxane chemotherapy (as in standard pertuzumab regimens) — please refer to the package insert for specifics
Emetogenicity Classification	Low (as monoclonal antibody); combination regimens follow the emetogenicity of the co-administered chemotherapy
Monitoring Items	Cardiac function (LVEF) at baseline and during treatment — a class-characteristic risk for anti-HER2 antibodies; CBC and infusion-reaction monitoring when combined with chemotherapy
Handling Protection	Standard biologic/monoclonal antibody handling precautions; not classified as a conventional cytotoxic requiring cytotoxic drug handling protocols

Safety Considerations

Please refer to the package insert for safety information. (No key warnings, contraindications, or drug interaction data are available in this evidence pack — DG001 identifies TFDA/US labeling warnings and contraindications as a blocking data gap.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The top-ranked prediction (PR-positive breast cancer) is supported by L1-level evidence, including multiple completed/ongoing RCTs directly evaluating pertuzumab-based regimens in HR+/HER2+ populations (e.g., PERTAIN, WSG-ADAPT, WSG-TP-II, DECRESCENDO). However, this predicted indication is a hormone-receptor subgroup within the drug’s existing HER2-positive approved population, not an independent mechanistic extension — HER2-positive status remains a prerequisite. Lower-ranked predictions (ranks 5–10: ectomesenchymoma, HHV-8-related tumor, etc.) have no clinical or literature support (L4–L5) and should be held.

To proceed, the following is needed:

TFDA/FDA labeling data — warnings, contraindications, and DDI information (blocking gap DG001)
Confirmed mechanism of action documentation (gap DG002)
Verification of HER2 status as an eligibility criterion in any protocol targeting PR+ breast cancer
Clarification of current US market/licensing status, since pertuzumab (Perjeta®) is known to be marketed elsewhere but shows zero licenses in this dataset
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.